GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Hormones & treatment · 7 MIN READ

UK BMS / NICE 2026 Menopause Practice Update: Seven Key Changes, With Theory and Evidence Explained

Full original restored

Use guidance to understand assessment and review, rather than treating a list of updates as a universal regimen.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.

UK BMS / NICE 2026 Menopause Practice Update: Seven Key Changes, With Theory and Evidence Explained

From “Do I need a blood test?” to “Can I use local estrogen after breast cancer surgery?”—unpacking the mechanisms and literature behind the guidelines

Written 2026-10-27 · Intended readers: obstetrician-gynecologists / endocrinologists / family physicians and patients interested in evidence

In the consultation room, 47-year-old Ms. Li hands over her phone. On the screen is a series of checked boxes in a “menopause self-test.” She asks, “Doctor, should I have a blood test to confirm this?”

This is precisely the kind of situation addressed in the British Menopause Society (BMS) and NICE practice updates of 2026-9. The updated advice provides more than ten key messages (this article selects seven for discussion), each with a defined mechanistic hypothesis and supporting evidence. Below, we explain “why” for each, as a reference for both clinical practice and education.

1

One. Age 45 and above: do not rely on blood tests to diagnose perimenopause / menopause

This is the most easily misunderstood point. The key is that diagnosis should not rely on a single blood test, but “looking at FSH trends” can still have value when there is another indication—the two are complementary, not contradictory.

Rationale

Perimenopause is a “transition,” rather than a “fixed state.” Ovulation becomes irregular and FSH can fluctuate markedly from month to month or even week to week. A single blood draw captures only “one moment” and can neither rule out nor confirm the condition. The STRAW+10 framework (Harlow et al., 2012) therefore stages it using menstrual-cycle changes, rather than a single hormone value: early transition = persistent changes in cycle length of ≥7 days from the individual's usual pattern; late transition = amenorrhea for ≥60 days.

Research and guideline sources

  • NICE NG23 (2026): In those over 45 with typical symptoms (new vasomotor symptoms + a change in menstrual pattern, or no period for ≥12 months without hormonal contraception), diagnosis can be clinical, without laboratory testing; FSH is explicitly not recommended in this population.
  • ASRM committee opinion (2020): Ovarian-reserve markers such as FSH vary substantially by cycle day and between cycles, limiting the value of a single measurement.
  • Where blood testing still belongs: Assessing POI at <40, supporting diagnosis at 40–45, and excluding “mimics” such as thyroid disease (8–10 times more common in women than men), iron deficiency (ferritin<30), and vitamin D/B12 deficiency.

Original article illustration

Geirangerfjord, Norway | Photograph by:

Diego Delso

,

CC BY-SA 4.0

In one sentence: above 45, use “symptoms + menstrual history” to characterize the condition; blood tests are for excluding other diseases, rather than “proving menopause.”

2

Two. MHT first line; fezolinetant for moderate-to-severe vasomotor symptoms when MHT is unsuitable

Menopausal hormone therapy (MHT, called HRT in UK guidelines) remains the gold-standard first line; for people with contraindications or who do not wish to use hormones, NICE formally included fezolinetant in its 2026 recommendations.

Rationale

The underlying hot-flash mechanism involves KNDy neurons (kisspeptin–neurokinin B–dynorphin) in the hypothalamic temperature-control center. Declining estrogen “disinhibits” neurokinin B (NKB) signaling → increased KNDy activity → instability of the thermoregulatory set point → hot flashes. MHT addresses the source through “estrogen replacement”; fezolinetant, an NK-3 receptor antagonist, directly blocks this signaling cascade, independent of the sex-hormone pathway. It therefore suits people with a history of hormone-sensitive cancer, previous VTE, an assessed risk greater than benefit (such as diabetes/cardiovascular disease), or a personal preference against hormones.

Research and guideline sources

  • NICE TA1143 (published 2026-03-31): Fezolinetant for moderate-to-severe vasomotor symptoms “when MHT is unsuitable,” with an estimated 500,000 women in England potentially benefiting.
  • Three RCTs including SKYLIGHT 1 (Lancet, 2023) (DAYLIGHT, SKYLIGHT 1/2): For people with ≥7 moderate-to-severe VMS episodes daily, fezolinetant significantly reduced frequency and severity versus placebo, with benefits emerging within the first few weeks and lasting 52 weeks.
  • Monitoring: A boxed warning for liver injury—liver-function tests at baseline + monthly for the first 3 months + at months 6 and 9; contraindicated in cirrhosis, severe renal impairment, and concomitant CYP1A2 inhibitors.

Original article illustration

City park, Bergen, Norway | Photograph by:

Olaf Meister

,

CC BY-SA 4.0

A reminder of its role:

Fezolinetant is an

alternative/second-line option

, rather than a replacement for MHT. NICE NG23 continues to maintain “MHT first line without contraindications,” consistent with ACOG's 2026 guideline No.13 and the IMS 2026 Rio congress's “strong recommendation for NK antagonists.”

3

Three. Long-term vaginal estrogen: addition is recommended even with systemic MHT

This addresses a common misconception: “I'm already taking or applying hormones. If I'm still dry down below, is the dose too low?”—Usually not; the local tissue needs local administration.

Rationale

In genitourinary syndrome of menopause (GSM), low estrogen directly causes vaginal epithelial thinning, reduced elasticity, higher pH, and loss of lactobacillus dominance, increasing susceptibility to urinary tract infections. GSM progressively worsens over time and does not resolve spontaneously. Systemic MHT can improve some symptoms, but local tissue symptoms can persist, because systemic circulation may “dilute” estrogen too much to reach sufficient local concentrations. Systemic absorption of low-dose vaginal estrogen is negligible; it can complement systemic MHT without conflict.

Research and guideline sources

  • NHS Lothian menopause management: Low-dose local vaginal estrogen is highly effective for genitourinary atrophy, taking effect over 3–6 months; long-term maintenance is recommended to prevent recurrence. It can be safely combined with systemic MHT.
  • AUA 2019 recurrent UTI guideline: Recommends vaginal estrogen to reduce risk in peri/postmenopausal women with recurrent UTI; adding it in those already using systemic MHT does not increase adverse events.
  • Safety: Low-dose vaginal estrogen has minimal systemic absorption, usually does not increase breast cancer/thrombosis/endometrial cancer risk, and generally does not require additional progestogen even with a uterus (unlike systemic MHT).

4

Four. High VTE / CVD risk (including BMI>30): prioritize transdermal over oral MHT

For the same active ingredient, administration route determines clotting risk—a point repeatedly emphasized in the major societies' 2026 consensus.

Original article illustration

Helsinki Cathedral, Finland | Photograph by:

Old Pionear

,

CC BY-SA 4.0

Rationale

Oral estrogen undergoes the hepatic first-pass effect, activating coagulation, increasing inflammatory mediators, and changing clotting proteins → increased VTE risk. Transdermal estrogen bypasses that effect, with VTE risk at standard therapeutic doses no higher than in the baseline population. Transdermal administration should therefore be preferred for people with high VTE/CVD risk factors.

Research and guideline sources

  • Asia-Pacific Menopause Federation (APMF) 2024 consensus: Assess VTE risk before prescribing (age>60, obesity, personal or family VTE history, thrombophilia); do not use oral MHT with a personal VTE history; transdermal estrogen is recommended at BMI>30; micronized progesterone/dydrogesterone have lower VTE risk.
  • BMJ 2026 (Berggreen et al., nationwide nested case-control study, 40,241 cases): Oral MHT versus nonuse → VTE HR 1.6 (1.5–1.8), ischemic stroke 1.3, myocardial infarction 1.2; no increased thrombotic risk was observed with transdermal treatment.
  • BMS/IMS/EMAS/RCOG/AMS joint statement: Transdermal estradiol is unlikely to increase VTE risk above that in nonusers.
  • NHS Somerset: Transdermal MHT started at <60 does not increase CVD risk, affect CVD mortality, or increase stroke.

Clinical action:

For high VTE risk (including BMI>30 and strong family history/thrombophilia), NICE advises “consider transdermal rather than oral”; refer high-risk patients to hematology before deciding.

5

Five. High breast cancer risk / after surgery: vaginal estrogen can be used

This is among the most frequently asked questions and the most likely to receive a blanket refusal. The conclusion needs stratification.

Rationale

Low-dose vaginal estrogen has minimal systemic absorption (blood estrogen remains within the normal postmenopausal range). Local benefits—relieving dryness, reducing recurrent UTI, and improving quality of life—usually outweigh the theoretical risk from systemic exposure. However, hormone-sensitive breast cancer is a special situation requiring individualization and discussion with the oncology team, rather than a blanket “yes” or “no.”

Original article illustration

Blekholmen, Stockholm, Sweden | Photograph by:

Holger.Ellgaard

,

CC BY-SA 3.0

Research and guideline sources

  • NHS Lothian / NICE position: Low-dose vaginal estrogen with a history of estrogen-sensitive breast or gynecological cancer should usually be discussed with a menopause clinic or oncology team.
  • Differences by treatment context: Usually acceptable during tamoxifen treatment; potentially less suitable with aromatase inhibitors (letrozole/anastrozole/exemestane), because AIs aim for comprehensive estrogen suppression, creating tension with local estrogen.
  • Progestogen question: Vaginal estrogen usually does not require routine added progestogen (often not even with a uterus), but active breast cancer or AI treatment warrants careful assessment.

Evidence-level reminder:

These conclusions come from observational evidence and specialist consensus,

not RCTs

. Decisions must rest on individualized risk communication and remain consistent with the patient's treating oncology team.

6

Six. POI diagnosis requires two FSH tests 4–6 weeks apart; use hormone therapy at least until average menopause age (51)

The logic for managing premature ovarian insufficiency (POI) differs entirely from natural menopause: it is “chronic estrogen deficiency,” and treatment aims to “replace until the age when it should normally be present.”

Rationale

POI is defined as age <40 + amenorrhea/infrequent periods for ≥4 months + elevated FSH (>25–30 IU/L) on two occasions. A single FSH measurement also fluctuates considerably (as in perimenopause), requiring confirmation after an interval. POI occurs more than 10 years earlier than natural menopause; prolonged deficiency significantly increases osteoporosis, cardiovascular, cognitive, and mood risks. Hormone therapy is therefore not “the lowest dose for the shortest time,” but replacement of hormones that should be secreted until the natural menopause age.

Research and guideline sources

  • NICE / WHO 2026: Suspected POI at <40 → two FSH tests 4–6 weeks apart, rather than relying on one blood test.
  • Christin-Maitre et al., Ann Endocrinol 2021: POI = <40 + amenorrhea>4 months + FSH>25 (twice, >4 weeks apart); HRT recommended at least to physiological menopause age 51.
  • POI's specific context: Breast cancer concerns differ from those in older women (this is “replacement,” rather than “extra addition”); spontaneous ovulation/pregnancy occurs in around 5–10%, so MHT is not contraception, and contraception needs separate discussion.

Original article illustration

Reykjavík street scene, Iceland | Photograph by:

Hedwig Storch

,

CC BY-SA 3.0

This supports the “duration of exposure hypothesis” discussed in this publication's earlier article, POI and Early Menopause: Understanding the Chronic Endocrine Disease Paradigm: treatment duration itself provides protection.

7

Seven. Use discussion aids to communicate MHT's long-term benefits and risks

This final point may seem “soft,” but it is essential to implementing the preceding six.

Rationale

MHT decisions are highly individual (timing window, baseline risk, preferences) and have long been affected by the post-WHI “fear narrative” and commercial misinformation. Structured shared decision aids can improve risk communication, reduce misunderstanding, and increase appropriate use. In 2025, the FDA removed boxed warnings concerning cardiovascular disease, breast cancer, and possible dementia from MHT labeling, opening space for rational communication; ACOG No.13 (2026) likewise places shared decision-making at its core.

What the tool should cover

  • Symptom burden and impact on quality of life;
  • Timing window (best benefit/risk ratio when started at <60 or within 10 years of menopause);
  • Baseline VTE / CVD / breast cancer risk assessment;
  • Route selection (transdermal preferred over oral in high-risk patients);
  • Nonhormonal alternatives (NK antagonists / SSRIs–SNRIs);
  • Follow-up and periodic reassessment plan.

Quick-reference reading

Quick-reference reading for clinicians

  1. NICE. Menopause: identification and management (NG23). 2026.
  2. Harlow SD, et al. STRAW+10 Collaborative Group. Fertil Steril. 2012. (Menstrual-cycle staging framework)
  3. ASRM Practice Committee. Testing and interpreting measures of ovarian reserve. 2020.
  4. NICE. Fezolinetant for moderate to severe VMS (TA1143). 31 Mar 2026.
  5. Lederman S, et al. SKYLIGHT 1. Lancet. 2023. (Phase III RCT of an NK-3 antagonist)
  6. Rance NE, et al. Front Neuroendocrinol. 2013. (KNDy-neuron hypothesis of hot flashes)
  7. NHS Lothian. Management of Menopause (section on vulvovaginal and lower urinary tract atrophy).
  8. AUA Guideline. Recurrent uncomplicated UTIs in women. 2019.
  9. Asia-Pacific Menopause Federation Consensus. J Menopausal Med. 2024.
  10. Berggreen J, et al. Contemporary MHT and thrombotic disease. BMJ. 2026;394:e100688.
  11. BMS/IMS/EMAS/RCOG/AMS Joint Statement on MHT and breast cancer risk. 2020.
  12. Christin-Maitre S, et al. POI position statement. Ann Endocrinol. 2021.
  13. ACOG Clinical Practice Guideline No.13. Obstet Gynecol. 2026;148:e345–e369.

Original article illustration

Trolltunga mountain landscape, Norway | Photograph by:

TerjeN

,

CC BY 3.0

Boundary statement:

This article is an evidence-based review and academic compilation drawing on public guidelines and literature,

not diagnosis, treatment advice, or a recommendation for any product

. Clinical decisions must reflect individual circumstances, follow current guidelines in the relevant country, and be made jointly by a fully informed patient and treating clinician. Initiating hormone therapy (MHT), and choosing formulation, dose, and duration, require individualized implementation after assessment of contraindications.

· Health education for women 40+

This publication follows evidence-based, noncommercial principles. Its focus remains:

Informed choice + bringing records to consultations + shared decisions with clinicians

.

If you have questions about this article, bring your own medical history and test results to discuss with your treating clinician.

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss care across borders